Vialon M, Grunenwald S, Mouly C, et al. - In this investigation, researchers assessed the prevalence of gestational diabetes (GD) in acromegalic women undergoing a systematic GD screening and then compared women with or without GD. Fourteen pregnancies were studied in 11 women (34.0 ± 3.6 years) treated with somatostatin analogues after a pituitary surgery (n = 6) or as primary (n = 5) therapy, and treatment for 13 pregnancies was discontinued at the moment of diagnosis. According to findings, women's prevalence of GD is higher than that reported in the literature, likely resulting from the systematic screening of GD and women's age. Therefore, routine GD screening should be considered in women with acromegaly, especially those with GD risk factors and prepregnancy levels of uncontrolled IGF-1.